B01AC16 • eptifibatide • Blood and blood forming organs | Antithrombotic agents | Platelet aggregation inhibitors excl. heparin
Eptifibatide is an antiplatelet medication used to prevent blood clot formation in patients with acute coronary syndromes or those undergoing coronary angioplasty procedures. It works by inhibiting platelet aggregation, thus reducing the risk of myocardial infarction or other cardiovascular complications.
Eptifibatide is administered intravenously under strict medical supervision, usually in a hospital setting, before, during, or after cardiac procedures. The dose is adjusted according to the patient's weight and the doctor's instructions.
Side effects may include bleeding, decreased platelet count, allergic reactions, or, rarely, hypotension. Careful monitoring of blood parameters is essential during treatment.
Eptifibatide is an effective option for reducing the risk of thrombotic complications in patients with heart conditions, but its use requires specialized medical supervision.
Substance: eptifibatide
Date of last drug list: 01-11-2023
Commercial code: W69407001
Concentration: 2mg / ml
Pharmaceutical form: injectible solution
Quantity: 1
Product type: generic
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: WAVE PHARMA LIMITED - ANGLIA
Holder: CN UNIFARM S.A. - ROMANIA
Number: 777/2023/01
Shelf life: 3 years